Remembering Frank Zappa and Understanding Prostate Cancer

A death at 52, from a disease of the seventies

Frank Zappa was a composer, guitarist, bandleader, and satirist whose work crossed freely between rock and modern classical music. He died on Saturday, December 4, 1993, at the age of 52. UPI reported the cause as prostate cancer. He had been living with it for several years. A private funeral was held the following day.

That is the public record. What his doctors found, and what he chose, were never made public. This page will not guess.

His age is the part worth pausing on. Prostate cancer is overwhelmingly a disease of older men, and Zappa was not one.

A common cancer that behaves unlike most

The prostate is a walnut-sized gland below the bladder that helps make semen. Cancer starting in it is the most commonly diagnosed cancer in American men.

The American Cancer Society estimated 333,830 new cases and 36,320 deaths in the United States for 2026, and SEER, NCI's cancer surveillance program, carries that projection. That gap between cases and deaths is the defining feature of this disease. SEER's own measurements put the rate of new cases at 123.2 per 100,000 men per year, the median age at diagnosis at 68, and 43.3 percent of new cases in men aged 65 to 74.

The National Cancer Institute puts the consequence plainly. Many patients, "especially those with localized tumors, may die of other illnesses without ever having suffered disability from prostate cancer." A prostate cancer diagnosis and a prostate cancer death are very different events. Most men who get the first never reach the second.

Symptoms are a poor early warning system

CDC states it directly: "Most men do not have symptoms at all." Early prostate cancer is usually silent, because a small tumor in the gland does not block anything.

When symptoms do appear, CDC lists trouble starting urination, a weak or interrupted stream, and urinating often at night. The list continues with trouble emptying the bladder, pain or burning while urinating, blood in the urine or semen, painful ejaculation, and constant pain in the back, hips, or pelvis. CDC adds that other conditions cause these too. An enlarged but benign prostate explains most of them far more often.

When to get checked

• Blood in the urine or semen, even once, warrants an appointment now rather than later
• Back, hip, or pelvic pain that has not let up for several weeks, especially at night
• Trouble starting, a weak stream, or getting up repeatedly at night to urinate
• Being unable to pass urine at all, which is an emergency
• Ask about screening starting at 55 if you are at average risk, and earlier if you have risk factors
• CDC names those risk factors: being African American, or having a father, son, or brother who had prostate cancer
• CDC also treats a diagnosis at age 55 or younger as a reason to look at inherited risk in the family

Screening is where the real debate sits

NCI notes that in the United States, most prostate cancers are now found through screening. That usually means a PSA blood test, and less often a digital rectal exam. PSA stands for prostate-specific antigen, a protein the gland releases into the blood.

The U.S. Preventive Services Task Force does not tell men what to do here, and that is deliberate. For men aged 55 to 69 it says "the decision to undergo periodic prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one." For men 70 and older, it recommends against PSA screening.

The Task Force quantifies both sides. Screening about 1,000 men for 13 years prevents roughly 1.3 deaths from prostate cancer and about 3 cases of cancer spreading to distant sites. Against that, more than 15 percent of screened men get a false positive result, and biopsies carry complications. Between 20 and 50 percent of screen-detected cancers are overdiagnosed, meaning they would never have caused harm. Treatment of those cancers still causes urinary incontinence and erectile dysfunction in a meaningful share of men.

No single answer fits everyone in that arithmetic. Your answer depends on your age, your risk, and which tradeoff you would rather live with.

From a raised PSA to a diagnosis

A high PSA is not a diagnosis. NCI states that "needle biopsy is the most common method used to diagnose prostate cancer," and that most urologists take the sample through the rectum using ultrasound guidance.

The pathologist then grades how the tumor looks using the Gleason system. The two most common patterns are each scored from 1 to 5, then added. A report of "Gleason score 3 + 4 = 7" means the dominant pattern was 3 and the secondary pattern was 4. Those scores are now folded into five grade groups, where grade group 1 covers Gleason 6 or less and grade group 5 covers Gleason 9 and 10.

Grade group is what separates a cancer that can be watched from one that needs treating now. NCI lists the other factors that shape prognosis as tumor extent, patient age and health, and PSA level. It adds that "the higher the level of PSA at baseline, the higher the risk of metastatic disease or subsequent disease progression."

What treatment involves

For localized disease, NCI lists active surveillance, surgery, radiation therapy, hormonal therapy, chemotherapy, immunotherapy, and supportive care. Active surveillance is a real plan, not a delay. It means regular PSA tests, exams, imaging, and repeat biopsies. Treatment is held in reserve, ready if the cancer shows it is changing.

Hormonal therapy is also called androgen deprivation therapy, and it works by cutting off the testosterone that prostate cancer feeds on. NCI adds a caution about reading its effects. Androgen deprivation "can decrease the serum level of PSA independent of tumor response." A falling PSA on hormone therapy does not by itself prove the tumor is shrinking.

For cancer that has reached distant organs, NCI is direct that "current therapy will not cure it," while noting survival varies considerably.

What the survival numbers mean here

SEER lists five-year relative survival for prostate cancer at 98.2 percent overall, using cases from 2016 through 2022. Broken out by stage, it is 100.0 percent for localized disease, 100.0 percent when nearby tissue or nodes are involved, and 40.1 percent once the cancer has reached distant sites.

Those first two figures are startling. They are also why overdiagnosis is a real problem rather than an abstract one. SEER records 69 percent of cases as localized at diagnosis and 9 percent as distant. These are group statistics from tens of thousands of men. They describe a population rather than a person.

Sources

• https://www.upi.com/Archives/1993/12/06/Musician-Frank-Zappa-is-dead-the-victim-of-cancer/1859755154000/
• https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq
• https://seer.cancer.gov/statfacts/html/prost.html
• https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening
• https://www.cdc.gov/prostate-cancer/symptoms/index.html
• https://www.cdc.gov/prostate-cancer/risk-factors/index.html